Pfizer Stock Underperforms Sector; Shares Decline Amid COVID-19 Sales Pressure
Pfizer Inc. (PFE), a global biopharmaceutical giant with a market capitalization of $154.3 billion, continues to navigate a dynamic pharmaceutical landscape, developing and distributing a broad range of medicines and vaccines across numerous therapeutic areas worldwide. The company’s operations encompass both the research and development of innovative treatments and the large-scale manufacturing and marketing of established medications and preventative vaccines, illustrating a comprehensive approach to healthcare solutions. As a “large-cap” stock valued at over $10 billion, Pfizer’s position within the market is undeniably significant, impacting investment strategies and influencing broader healthcare trends. The company’s portfolio boasts a diversified collection of treatments spanning cardiovascular disease, infectious diseases, immunology, oncology, rare diseases, and, critically, COVID-19 prevention and treatment, featuring recognizable brands such as Eliquis, Prevnar, Comirnaty, Paxlovid, and Ibrance. Recent market activity surrounding Pfizer reflects both positive short-term gains and underlying concerns regarding the company’s future trajectory.
Specifically, Pfizer’s stock has shown upward momentum over the past three months, increasing by 7.6%, which outpaced the State Street Health Care Select Sector SPDR ETF (XLV)’s 1.7% gain during the same period. Furthermore, on a year-to-date (YTD) basis, PFE stock has delivered a robust performance, rising by 9%, significantly exceeding XLV’s 2% increase. However, this favorable performance is juxtaposed with a more cautious assessment of the company’s longer-term prospects, as shares have only risen by 1.8% over the past 52 weeks, lagging behind XLV’s 6.9% return. This divergence highlights a key point of contention among investors and analysts alike.
The current market sentiment is largely shaped by a recent announcement of reaffirmed guidance for 2026, which projected a revenue decline primarily driven by patent cliffs and ongoing headwinds from decreasing sales of COVID-19 products. Pfizer’s forecast indicates a 2026 revenue range of $59.5 billion to $62.5 billion, alongside adjusted earnings per share (EPS) estimates of $2.80 to $3.22, down from $62.6 billion in 2025 revenue and $3.22 EPS, taking into account tariff impacts and anticipating only approximately $5 billion in revenue from COVID-19 related products. While Pfizer reported better-than-expected Q4 2025 revenue of $17.6 billion and EPS of $0.66, the market’s attention was immediately drawn to the downward revisions of key product sales, particularly a decline of roughly 70% in Paxlovid sales and 35% in Comirnaty sales year-over-year. These reductions underscore intensifying concerns regarding the sustainability of Pfizer’s revenue streams beyond its continued COVID-19 defenses.
To provide a comparative context, Amgen Inc. (AMGN) has demonstrated stronger performance recently, returning 17% on a YTD basis and 23.6% over the past 52 weeks, showcasing a contrasting growth story. Despite these impressive gains for Amgen, analysts remain largely cautious regarding Pfizer’s prospects, reflected in a “Hold” consensus rating from 27 analysts covering the stock, with a mean price target of $28.58 – a premium of 5.3% to its current trading level. This cautious stance is largely attributable to the considerable uncertainties surrounding Pfizer’s ability to transition its product portfolio and maintain profitability in the face of evolving market dynamics and competitive pressures. As of the publication date, Sohini Mondal did not hold (either directly or indirectly) any positions in the securities mentioned. All data and information presented herein is strictly for informational purposes.
